Journal of
Neuroinfectious Diseases

Editorial Open Access

Introduction

Ne onal face a oan ibod -media ed encephali i (NSAME) ha eme ged a a p ominen and e ol ing a ea i hin he ealm of ne oimm nolog , i h inc ea ing ecogni ion of i clinical igni cance and comple .i . NSAME encompa e a g o p of a oimm ne di o de cha ac e i ed b he p od c ion of a oan ibodie di ec ed again peci c ne onal face an igen . e e a oan ibodie di p no mal ne al ignaling, leading o a di e e a a of ne ological and p chia ic mp om , o en p e en ing diagno ic challenge fo clinician [1]. Unde anding he pa hogenic pa h a ha nde lie NSAME i c cial fo el cida ing i e iolog , de eloping a ge ed ea men , and imp o ing pa ien o come . e hallma k of NSAME i he p e ence of a oan ibodie ha a ge a a ie of ne onal face p o ein , incl ding b no limi ed o NMDA ecep o , LGI1, CASPR2, and GABA (B) ecep o . e e a oan ibodie can di ec l impac nap ic an mi ion and ne onal f nc ion, leading o he de elopmen of cha ac e i ic clinical manife a ion ch a e i e , cogni i e de ci , beha io al abno mali ie , and mo emen di o de [2]. e ecogni ion of di inc a oan ibod p o le ha allo ed fo imp o ed diagno ic p eci ion and ailo ed he ape ic app oache . Be ond he peci c a oan ibodie , NSAME pa hogene i in ol e in ica e in e ac ion be een gene ic p edi po i ion, en i onmen al igge , and imm ne d eg la ion [3]. Gene ic fac o ma in ence an indi id al' cep ibili o NSAME, hile a io en i onmen al fac o , ch a infec ion , mo , o o he imm ne challenge , can e e a po en ial igge fo he a oimm ne e pon e. D eg la ed imm ne e pon e i hin he cen al ne o em, incl ding he ec i men of in amma o cell and he ac i a ion of complemen pa h a , f he con ib e o he pa hogenic ca cade in NSAME. i in od c ion e he age fo a comp ehen i e e.plo a ion of he pa hogenic pa h a in ol ed in NSAME, highligh ing he comple.y in e pla be een a oimm ni , ne oin amma ion, and ne onal d f nc ion. A o nde anding of NSAME con in e o e ol e, n a eling he e in ica e mechani m hold he p omi e of imp o ed diagno ic c i e ia and he de elopmen of mo e e ec i e he ape ic in e en ion fo indi id al a ec ed b hi challenging ne ological di o de . He e e ill foc on mechani ic a pec of he e ne onal a oan ibod -media ed nd ome and highligh a ea of c en and f e in e e [4, 5].

Discussion

e di c ion of pa hogenic pa h a in ne onal face a oan ibod -media ed encephali i i a c i ical a pec of nde anding he nde l ing mechani m , clinical implica ion , and po en ial he ape ic a ge fo hi condi ion. Ne onal face a oan ibodie ha e been a ocia ed i h a ange of ne ological di o de , incl ding encephali i , and he a e ho gh o pla a cen al ole in he pa hogene i of he e di ea e . In hi di c ion, e ill e.plo e he c en kno ledge and eme ging in igh in o he pa hogenic pa h a in ol ed in ne onal face a oan ibod -media ed encephali i [6]. One of he ke fea e of ne onal face a oan ibod -media ed encephali i i he p e ence of an ibodie ha a ge peci c ne onal face p o ein . e e a oan ibodie can di p no mal ne onal A n

aims to elucidate the intricate interplay between autoimmunity, neuro

improving the quality of life for a fected individuals.

***Corresponding author:** Arun J. Gill, Division of Neuroimmunology and Neuroinfectious Diseases, USA, E-mail: a.jgill@jhmi.edu

Received: 31-Aug-2023, Manuscript No: JNID-23-114813; **Editor assigned:** 01-Sep-2023, Pre-QC No: JNID-23-114813 (PQ); **Reviewed:** 15-Sep-2023, QC No: JNID-23-114813; **Revised:** 20-Sep-2023, Manuscript No: JNID-23-114813 (R); **Published:** 27-Sep-2023, DOI: 10.4172/2314-7326.1000468

Citation: Gill AJ (2023) Pathogenic Pathways in Neuronal Surface Autoantibody-Mediated Encephalitis. J Neuroinfect Dis 14: 468.

can facili a e ea lie diagno i , p edic ea men e pon e , and help iden if pa ien a i k of elap e.

Personalized medicine approaches:

Acknowledgment

None

Con ict of Interest

None

References

1. Grant I (1987) in the acquired immunodefciency syndrome (AIDS) and other human immunodefciency virus (HIV) infections: studies with neuropsychologic testing . Ann Intern Med 107: 828-836.

2. Ellis RJ, Deutsch R , Heaton R K , Marcotte T D , McCutchan J A, et al. (1997) Neurocognitive impairment is an independent risk factor for death in HIV . Arch Neurol 54: 416-424.

   Becker JT (2015) Cohort profle: recruitment cohorts in the neuropsychological substudy of the Multicenter AIDS Cohort Study. Int J Epidemiol 44: 1506-1516.

4. Amudhan S, Gururaj G, Satishchandra P (2015) Epilepsy in India I: . Ann Indian Acad Neurol 18: 263-277.

5. Nash TE, Garcia HH (2011) Diagnosis and Treatment of Neurocysticercosis Nature reviews Neurology 7: 584-594.

6. Garcia HH, Nash TE, Del Brutto OH (2014) . Lancet Neurol 13: 1202-1215.

7. Kimura-Hayama E T, Higuera J A, Corona-Cedillo R, Chávez-Macías L, Perochena A, et al. (2010) Neurocysticercosis: radiologic-pathologic correlation Radiographics 30: 1705-1719.

8. Lerner A, Shiroishi MS, Zee CS (2012) Imaging of neurocysticercosis Neuroimaging Clin N Am 22: 659.

9. Castillo M (2004) Imaging of neurocysticercosis. Semin Roentgenol 39: 465-473.

10. Hingwala, Divyata (2011) Applications of 3D CISS Sequence for Problem . The Indian Journal of Radiology Imaging 21: 90-97.

11. Govindappa SS, Narayanan JP, Krishnamurthy VM (2000) Improved

    constructive interference in steady state MR sequence. AJNR Am J Neuroradiol 21: 679-684.

12. Zhao J L, Lerner A, Sh Z, Gao X J, Zee C S (2015) Imaging spectrum of . Radiology of Infectious Diseases, 1: 94-102.

13. Braga F, Rocha A J, Gomes H R, Hernandez Filho G, Fonseca RB (2004) Noninvasive MR cisternography with fuid-attenuated inversion recovery and 100% supplemental O2 in the evaluation of neurocysticercosis. AJNR Am J Neuroradiol 25: 295-297.

14. Garcia H H, Castillo Y, Gonzales I, Bustos J A , Saavedra H, et al. (2018) Cysticercosis Working Group in Peru. Low sensitivity and frequent crossreactions in commercially available antibody detection ELISA assays for . Tropical Medicine & International Health 23:101-105.